Chronic Pain Clinical Trial
Official title:
Electrophysiological Correlates of Nocebo Effects on Pain
Pain is a nociceptive somatosensory process that can arise as a debilitating and chronic symptom in various diseases or following an injury. How pain is experienced can vary widely within and across individuals, and can be shaped by cognitive processes such as learning. Nocebo effects, negative changes in symptom severity attributed to learned outcome-expectations, demonstrate how learning processes can be detrimental for the experience of pain. Research to date has produced inconclusive findings regarding the electrophysiological correlates on nocebo effects. The few studies that have applied electroencephalography (EEG) in this field have pointed towards a potential involvement of alpha-band activity, but the direction of this involvement remains unclear. For example, an EEG study of conditioned nocebo hyperalgesia found a pre to post increase in resting state alpha band power that was correlated with pain catastrophizing scores and not with the magnitude of the nocebo effect. Later, other studies also found pre to post changes in alpha band power, however, these changes were correlated with the magnitude of nocebo effects and not pain catastrophizing. Given the discrepancy in findings, in this study the investigators plan to primarily investigate whether EEG components predict the magnitude of nocebo responses to thermal-pain stimuli. The investigators will also explore electrophysiological correlates during pain anticipation and whether nocebo responses would be significantly related to spectral and temporal EEG biomarkers. This study will utilize a validated model of instructional and associative learning methods (i.e., negative suggestions and classical conditioning, respectively) to experimentally induce nocebo effects on heat-evoked pain. Developing objective, brain-derived markers for nocebo responses, or the detection of individuals most susceptible to nocebo hyperalgesia, will aid in the comprehensive management of pain. This study is conducted at Leiden University.
Main outcome variable for nocebo responses:
- The magnitude of induced nocebo hyperalgesia is defined as the difference in pain ratings
for the first nocebo trial compared to the first control trial of the evocation phase.
Note: A significant difference will be assessed using a Repeated Measures ANOVA as a
manipulation check. Then, calculated difference scores represent the magnitude of induced
nocebo hyperalgesia and will be used for the primary and first and second secondary
hypotheses.
Definitions of other outcome variables:
- The magnitude of nocebo responses (and nocebo-augmented pain) during the evocation phase is
defined in the specific nocebo evocation trials that show heightened pain relative to the
preceding control trials, for each subject. For EEG analyses, all trials that show the
experience of heightened pain in nocebo trials relative to the preceding control trials,
during the evocation phase will be used.
Note: Calculated difference scores between the specific nocebo evocation trials that show
heightened pain relative to control trials will be used in further analyses of EEG data.
While the entirety of the evocation data will be reported and analyzed, the main EEG analyses
will include a selection of evocation trials where nocebo responses were reported. It is
necessary to use EEG data for trials that show a nocebo response in order to explore
electrophysiological correlates of nocebo effects.
0. Manipulation checks: Induction of nocebo hyperalgesia First, the investigators will
examine whether significant nocebo hyperalgesia was induced. A Repeated-Measures Analysis of
Variance (RM ANOVA) will be performed for nocebo responses (on the pain Numeric Rating
Scale), with trial type as the within-subjects factor with two levels (first nocebo evocation
trial, first control evocation trial). First evocation trial pairs were chosen based on the
clearest effects being observed during piloting and in previous nocebo studies.
1. Primary hypothesis:
Pre-induction to post-induction decreases in resting-state alpha band power will
positively correlate with the magnitude of induced nocebo hyperalgesia.
2. Secondary hypotheses:
2.1. The magnitude of induced nocebo hyperalgesia in all nocebo-response evocation
trials, will be related to temporal (e.g., Detrended Fluctuation Analysis) and spectral
(e.g., Absolute Power, Relative Power and Central Frequency) biomarker values of alpha,
beta, and gamma oscillations.
2.2. The experience of nocebo-augmented pain in nocebo trials and pain during control
trials of the evocation phase will be characterized by divergent alpha, beta, and gamma
oscillation power and peak frequencies.
2.3. The experience of nocebo-augmented pain in nocebo evocation trials and baseline
high-pain stimulations, will be characterized by divergent alpha oscillation power and
peak frequencies.
2.4. The experience of control and nocebo trials during the induction phase, will be
characterized by divergent alpha, beta, and gamma oscillation power and peak
frequencies.
2.5. Nocebo induction trials will be characterized by increased gamma band coherence
relative to control induction trials during anticipation.
3. Questionnaires To assess the influence of psychological and personality traits,
questionnaires will also be included. These will include the Pain Catastrophizing Scale
(PSC), the Fear of Pain Questionnaire-III (FPQ-III), the Experience of Cognitive
Intrusion of Pain (ECIP) scale, and the Amsterdam Resting State Questionnaire (ARSQ
2.0).
3.1. Correlation analyses will be performed between scores on the questionnaires and the
magnitude of the nocebo effect.
3.2. Correlation analyses will be performed between scores on the questionnaires and measures
of EEG, as well as pre-to post resting-state differences, in alpha, beta, and gamma frequency
bands.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|